MetS Risk Score: A Clear Scoring Model to Predict a 3-Year Risk for Metabolic Syndrome

Authors

Tian-Tian Zou^{1,2}, Yu-Jie Zhou^{1,3}, Xiao-Dong Zhou⁴, Wen-Yue Liu⁵, Sven Van Poucke⁶, Wen-Jun Wu⁵, Ji-Na Zheng^{1,3}, Xue-Mei Gu⁵, Dong-Chu Zhang⁷, Ming-Hua Zheng^{1,8}, Xiao-Yan Pan⁵

Affiliations

- 1 Department of Hepatology, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 2 School of the Second Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China
- 3 School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China
- 4 Department of Cardiovascular Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 5 Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 6 Department of Anesthesiology, Ziekenhuis Oost-Limburg, Genk, Belgium
- 7 Wenzhou Medical Center, Wenzhou People's Hospital, Wenzhou, China
- 8 Institute of Hepatology, Wenzhou Medical University, Wenzhou, China

Key words

metabolic syndrome, prediction model, risk factors, general population

received 13.02.2018

accepted 06.08.2018

Bibliography

DOI <https://doi.org/10.1055/a-0677-2720>

Horm Metab Res 2018; 50: 683–689

© Georg Thieme Verlag KG Stuttgart · New York

ISSN 0018-5043

Correspondence

Ming-Hua Zheng, MD, PhD
Department of Hepatology
Liver Research Center
The First Affiliated Hospital of Wenzhou Medical University
Institute of Hepatology
Wenzhou Medical University
No. 2 Fuxue Lane
325000 Wenzhou
China

Tel.: +86/577/88078 232, Fax: +86/577/88078 262
blueman1320@163.com

Xiao-Yan Pan, MD
Department of Endocrinology
The First Affiliated Hospital of Wenzhou Medical University
No. 2 Fuxue Lane
325000 Wenzhou
China
Tel.: +86/138/57735 773, Fax: +86/577/55579 329
xiaoyanpan@wmu.edu.cn

Supplementary material for this article is available online at <http://www.thieme-connect.de/products>

ABSTRACT

Although several risk factors for metabolic syndrome (MetS) have been reported, there are few clinical scores that predict its incidence. Therefore, we created and validated a risk score for prediction of 3-year risk for MetS. Three-year follow-up data of 4395 initially MetS-free subjects, enrolled for an annual physical examination from Wenzhou Medical Center were analyzed. Subjects at enrollment were randomly divided into the training and the validation cohort. Univariate and multivariate logistic regression models were employed for model development. The selected variables were assigned an integer or half-integer risk score proportional to the estimated coefficient from the logistic model. Risk scores were tested in a validation cohort. The predictive performance of the model was tested by computing the area under the receiver operating characteristic curve (AUROC). Four independent predictors were chosen to construct the MetS risk score, including BMI (HR = 1.906, 95% CI: 1.040–1.155), FPG (HR = 1.507, 95% CI: 1.305–1.741), DBP (HR = 1.061, 95% CI: 1.002–1.031), HDL-C (HR = 0.539, 95% CI: 0.303–0.959). The model was created as –1.5 to 4 points, which demonstrated a considerable discrimination both in the training cohort (AUROC = 0.674) and validation cohort (AUROC = 0.690). Comparison of the observed with the estimated incidence of MetS revealed satisfactory precision. We developed and validated the MetS risk score with 4 risk factors to predict 3-year risk of MetS, useful for assessing the individual risk for MetS in medical practice.

Abbreviations

ALB	Albumin
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
AUROC	The area under the receiver operating characteristic curve
BMI	Body mass index
CI	Confidence interval
Cr	Creatinine
DBP	Diastolic blood pressure
FPG	Fasting plasma glucose
GGT	γ -Glutamyl transferase
HDL-C	High-density lipoprotein cholesterol
HR	Hazard ratio
LDL-C	Low-density lipoprotein cholesterol
MetS	Metabolic syndrome
NAFL	Non-alcoholic fatty liver
PLT	Platelet count
ROC	Receiver operator characteristic
SBP	Systolic blood pressure
STB	Serum total bilirubin
TC	Total cholesterol
TG	Triglyceride
UA	Uric acid
WBC	White blood cell count

Introduction

Metabolic syndrome (MetS), characterized by a group of metabolic disturbances including central obesity, glucose intolerance, hypertension, and hyperlipidemia [1] is a growing public health problem worldwide [2] with an increasing prevalence [3]. Additionally, MetS is associated with the risk of diabetes, cardiovascular disease, and even death [4–6]. Therefore, more attention should be paid to the prevention of MetS. A prediction model, which is able to identify the individuals with higher risk of MetS development, is urgently needed to estimate the risk of MetS leading to proper interventions at an earlier stage.

Previous studies have reported many related risk factors associated with the incidence of MetS [7–9], such as uric acid (UA), γ -glutamyl transpeptidase (GGT), and alanine aminotransferase (ALT). However, there are few studies grouping these factors to develop a model and predict the risk of MetS. Only one study [10] published in 2015 has identified several independent risks and created a composite score to predict the incidence of MetS. Based on a Japanese employees database, a model was developed to discriminate MetS from healthy individuals and evaluated the predictive potential for recovery from MetS. However, the model contains nine variables including five used to diagnose MetS plus four independent factors, limiting its application.

In this study, we identified four items related to the MetS, constructed and validated a clear model based on routine laboratory and anthropometric parameters to predict a 3-year risk of MetS.

Subjects and Methods

Study population

In this study, we screened 4395 initially MetS-free patients who underwent an annual health examination at Wenzhou Medical Center of Wenzhou People's Hospital from 2010 to 2014. The examination includes anthropometric measurements, blood tests, and a physical examination. The entire database was then randomly divided in a 2:1 ratio into training (1365 males and 1565 females, age 41.75 ± 14.70 years) and validation cohort (681 males and 781 females, age 41.95 ± 14.89 years). In addition, verbal informed consent was obtained from each participant and the protocol of the study was approved by the ethics committee of the Wenzhou People's Hospital, respectively.

Event criteria

MetS was defined according to the guidelines as proposed by the China Diabetes Federation [11], which indicates that MetS is present if at least three of the following parameters are present: 1) Central obesity: BMI ≥ 25 in both genders; 2) Hypertriglyceridemia: TG ≥ 1.7 mmol/l; HDL-C < 0.9 mmol/l in males and < 1.0 mmol/l in females; 3) Hypertension: SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or previously diagnosed; and 4) Hyperglycemia: FPG ≥ 6.1 mmol/l, or hyperglycemia previously diagnosed.

Data collection

All subjects were instructed to refrain from exercise prior to their examination with clinical examination and data recording conducted the next morning. Medical history, lifestyle, and drug regimes were recorded by well-trained medical staff. Anthropometric measurements included body height and weight. The body mass index (BMI), was calculated by dividing weight (kg) by the square of height (m). Blood pressure, including systolic blood pressure (SBP) and diastolic blood pressure (DBP), was measured automatically (OMRON, Japan), lege artis. Fasting blood samples were collected from each subject and were used for the analysis of biochemical laboratory test. The laboratories were certified according to International Organization Standardization. Laboratory parameters included albumin, white blood cell counts (WBC), blood urea nitrogen (BUN), triglyceride (TG), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), serum total bilirubin (STB), fasting plasma glucose (FPG), serum creatinine (sCr), serum uric acid (sUA), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ -glutamyl transferase (GGT). All values were subsequently analyzed by an automated analyzer (Abbott AxSYM, Park, IL, USA) using standard methods.

Statistical analysis

Continuous variables were summarized as mean $\pm$ standard deviation (SD), and categorical variables were expressed as percentages (%). The characteristics of the study population according to database were assessed using one way analysis of variance (ANOVA) and χ^2 test for categorical variables. Univariate and multivariate logistic regression analyses were used to determine the risk factors for MetS. Additionally, a stepwise multivariable logistic regression model was employed to develop a predictive model from the training cohort. For all analysis, two-tailed p-value < 0.05 were consid-

ered statistically significant and a p-value <0.1 was considered indicative of a statistical trend. Data analyses were conducted using SPSS statistics software (version 22; IBM Corp.) and MedCalc version 12.7 (MedCalc Software).

Variable selection

First, several potential MetS risk factors based on recent literature were selected for evaluation. Univariate association analysis including potential risk factors was conducted and variables with $p < 0.05$ were considered significant. Finally we retained, the four variables that performed well both in the univariate and multivariate analysis for the final model.

Construction of the MetS risk score

For the training cohort, we translated continuous risk factor variables into categorized variables first, and then performed stepwise multivariable logistic regression analysis to compute β -coefficients for the four variables. For the analysis, the conditional probabilities used for the entry and removal of a factor were 0.05 and 0.10, respectively. Then, we established a scoring system that assigned risk scores to each variable based on the magnitude of its β -coefficient in the multivariable logistic regression model. A sum score, which was named the MetS risk score, was calculated for each participant by adding the scores for four variables together. The mean 3-year risk of all possible combinations of risk factors for a specific total

score was computed to obtain 3-year risk values (► Fig. 2). To assess the predictive potential of the model to discriminate “events” from “nonevents”, the area under the receiver-operating characteristic curve (AUROC) was calculated.

Validation of the MetS risk score

The performance of the risk score was evaluated in the validation cohort and entire sample. The predictive performance of the MetS risk score was evaluated using the AUROCs.

Results

Baseline characteristics of cohort population

A total of 10419 individuals were initially recruited into the study. Only 4395 (2930 in training cohort and 1465 in validation cohort) individuals were enrolled according to exclusion criteria (► Fig. 1). Baseline clinical and biochemical parameters of training and validation cohort are summarized in Table 1S. No significant difference was found between the training ($n = 2930$) and the validation cohorts ($n = 1465$).

Table 2S shows that patients who developed MetS in 3 years had an older age (44.28 vs. 41.52, $p = 0.006$), a higher BMI (22.98 vs. 21.97, $p < 0.001$), FPG (5.60 vs. 5.19, $p < 0.001$), SBP (123.74 vs. 120.22, $p = 0.001$), DBP (74.32 vs. 77.03, $p < 0.001$), UA (293.74 vs.

► Fig. 1 Study flow diagram.

Step1. Assign a score

BMI	Score
<24	0
≥ 24	1.5

FPG	Score
<5.2	0
≥ 5.2	1.5

HDL	Score
<1.4	0
≥ 1.4	-1.5

DBP	Score
<73.5	0
≥ 73.5	1

Step2. Add scores together

Risk factor	Score
BMI	_____
FPG	_____
HDL	_____
DBP	_____
Total	_____

Step3. Find absolute risk

Total Score	3-year risk(%)
-1.5	0.0
-0.5	0.9
0	4.8
1	6.6
1.5	9.9
2.5	12.6
3	18.4
≥4	≥24.1

► Fig. 2 Score sheet for estimating 3-year risk of MetS incidence.

278.49, $p = 0.029$), GGT (32.72 vs. 25.66, $p < 0.001$), and lower HDL-C (1.31 vs. 1.38, $p < 0.001$) in the training cohort while LDL-C, TC and Cr showed no significant difference. The patients' conditions were similar to the validation cohort.

Development of the MetS risk score

To identify independent predictors of MetS, the univariate logistic regression analysis was performed to test the relationships between the potential risk factors and the incidence of MetS in the training cohort (Table 3S). In the univariate analysis, we found that age, BMI, SBP, DBP, TG, TC, FPG, GGT, HDL-C, UA, and WBC were significantly associated with MetS development (all $p < 0.05$).

The above variables that were significantly associated with the risk of MetS were consequently entered into the multivariable logistic regression analysis to select independent predictors. Finally, as presented in ► Table 1, BMI (HR = 0.091, 95% CI: 1.040–1.155), FPG (HR = 1.507, 95% CI: 1.305–1.714, $p < 0.001$), DBP (HR = 0.016, 95% CI: 1.002–1.031), HDL (HR = 0.539, 95% CI: 0.303–0.959), were identified as the independent risk factors.

► Table 2 illustrates the results of the multivariate logistic regression performed on the 4 variables and the method to calculate the MetS score. For these 4 variables, the cut-off value of each parameter to distinguish two severity categories with maximum

► Table 1 Multivariate analysis of the association between incidence and clinical and biochemical characteristics in the training cohort.

Variables	B	HR	95% CI	p-Value
BMI	0.091	1.096	1.040–1.155	0.001
FPG	0.410	1.507	1.305–1.741	<0.001
DBP	0.016	1.016	1.002–1.031	0.021
HDL-C	-0.617	0.539	0.303–0.959	0.035

B: Intercept. For abbreviations, see text.

Youden Index in order to predict the risk of MetS was calculated. Then we derived an integer or half-integer score for prediction based on the multivariable logistic regression coefficients. The lowest value of β -coefficients was chosen to obtain a score of 1. Other β -coefficient values were then divided to the lowest value and resulted as score for each variable. Each point was rounded to an integer and half-integer. As a result, we assigned 1.5 points to the predictor BMI (kg/m^2) ≥ 24 and FPG (mmol/l) ≥ 5.2 , -1.5 points to the predictor HDL-C (mmol/l) ≥ 1.4 and 1 point to the predictor

► **Table 2** MetS risk score based on multivariable analysis of risk factors for MetS in the training cohort.

Categorical variable	Range	β	p-Value	HR (95% CI)	Risk score
BMI (kg/m ²)	<24	Reference	–	1.00	0
	≥24	0.790	<0.001	2.204 (1.661–2.924)	1.5
FPG (mmol/l)	<5.2	Reference	–	1.00	0
	≥5.2	0.695	<0.001	2.004 (1.524–2.637)	1.5
HDL-C (mmol/l)	<1.4	Reference	–	1.00	0
	≥1.4	–0.780	<0.001	0.458 (0.312–0.612)	–1.5
DBP (mmHg)	<73.5	Reference	–	1.00	0
	≥73.5	0.467	0.001	1.595 (1.199–2.123)	1

► **Fig. 3** Receiver operating characteristic curves analysis of the discriminative ability of MetS risk score to predict 3-year MetS development risk in the general population.

DBP (mmHg) ≥ 73.5. The final score per subject ranged from –1.5 to 4. A risk estimation chart based on combinations of different points of the four predictors in the MetS risk score was drawn for individual risk prediction (► **Fig. 4**).

Performance of MetS score in the training cohort

► **Fig. 3** illustrates the ROC curves in the training cohort, validation cohort and entire sample. The area under the receiver operating characteristic curve (AUROC) was 0.674 for training cohort, 0.690 for validation cohort and 0.680 for the entire database, implying that the discrimination of the model was good. Observed and pre-

BMI		<24	≥24	<24	≥24
FPG	HDL-C	DBP<73.5		DBP≥73.5	
<5.2	<1.4	6.1	10.1	6.6	13.6
	≥1.4	0.0	0.0	0.9	6.3
≥5.2	<1.4	10.0	8.1	9.9	24.0
	≥1.4	1.3	15.0	6.7	25.0

Low: <5%
Intermediate: 5-9.9%
High: ≥10%

► Fig. 4 Risk estimation chart of MetS risk score.

dicted ratios of 3-year incidence/risk (%) of MetS was detailed in Fig. 1S, which was calculated according to risk values revealed in ► Fig. 2, suggesting no significant difference between observed and predicted ratios in both training cohort (8.98 % vs. 8.16 %) and validation cohort (8.66 % vs. 8.73 %).

Discussion

In this study, we established and validated a new MetS risk score to predict the risk of MetS within the next three years. To our knowledge, this is the first study that developed a prediction score for incident MetS using the components of MetS. According to the result of the AUROC, the model showed a good predictability. Physicians can employ the MetS Risk Score to make individual predictions easily, and identify those potential patients and inform them to promote healthier behaviors to prevent the disease.

As we know, there are many diagnostic criteria of MetS around the world [11–13], such as the criteria from the Joint Interim Statement of the International Diabetes Federation Task Force of Epidemiology and Prevention American Heart Association, World Heart Federation, International Atherosclerosis Society, American Heart Association, International Association for the Study of Obesity and China Diabetes Federation. Finally, considering the composition of the population and the popularity of the criteria, MetS was diagnosed according to the China Diabetes Federation, which was composed of Central Obesity, Hypertriglyceridemia, Hypertension and Hyperglycemia.

Several risk factors of MetS have been identified in our study. First, we found that abdominal obesity (BMI) ($\beta = 0.790$, $HR = 2.204$) was the most important contributor to the incidence of MetS among the four items included in the score, which is in line with others [14] indicating that intra-abdominal fat is a major determinant for the metabolic syndrome. Recent researches [15, 16] showed that GGT is also associated with the risk of developing MetS, which was also identified in our study. The mechanisms have not been fully elucidated, but a study found that GGT may contribute to incident MetS via inflammation, oxidative stress pathways and insulin resistance [17]. However, due to the poor performance in the multivariable logistic regression analysis, it was not included in the score. Although the effect of gender difference on the incidence of the syndrome remains uncertain, we discovered that female sex could also be regarded as a risk score as a previous study

demonstrated that female sex is an independent item to predict MetS in the United States [18]. Therefore, further research is required to validate if female sex can also be regarded as a risk factor in Asian population. Additionally, non-alcoholic fatty liver (NAFL) demonstrated a tight connection with the MetS [19]. Its components have also been reported to independently predict the risk of NAFL in a northern urban Han Chinese population [20]. However, we found no significant association between MetS and NAFL in our study. One possible explanation is that NAFL may gradually disappear in a 3-year follow up not directly predicting the appearance of MetS. Elevated uric acid was also reported to be associated with MetS, which was confirmed in several studies [8, 21, 22]. The exclusion of this important factor may have influenced the difference of diagnostic criteria. Finally, considering the performance both in multivariate analysis and AUROC, we identified four risk factors, BMI, FPG, HDL-C and DBP in our model.

There are several strengths shown in our study. First, this is the first clean model based on routine laboratory and anthropometric parameters to predict a 3-year risk of MetS. The items included in the model are easy to obtain facilitating implementation. Individuals, who were identified at high-risk for MetS, can initiate a healthier lifestyle.

Despite the strengths of the present study, there are some limitations that need to be addressed. First, diagnoses of MetS in our study were based on the China Diabetes Federation, which is not universally implemented but considered most suitable for our study. Second, because of insufficient information retrieval, we could not evaluate lifestyle related parameters such as smoking, drinking and physical activity in this study [23]. Third, related with a limited dataset, the scoring model was not validated in different centers. We randomly divided the data into two parts: one to build the model and another to validate its performance. Validation could be optimized by X-validation. Further research is required to validate the scoring model in other multicenter studies.

Conclusions

In conclusion, we have developed a clear scoring model, the MetS risk score, for evaluating the 3-year risk of MetS individually. Our model identified 4 predictors to score the risk and performed well both in the training cohort and validation cohort.

Authors' Contributions

Tian-Tian Zou: designed the study, did the statistical analyses, interpreted data, and wrote the manuscript. Yu-Jie Zhou: did the statistical analyses and collected data. Xiao-Dong Zhou and Wen-Yue Liu: interpreted data and revised the manuscript. Sven Van Poucke: revised the manuscript. Wen-Jun Wu and Dong-Chu Zhang: data collection. Ji-Na Zheng and Xue-Mei Gu: interpreted data. Ming-Hua Zheng and Xiao-Yan Pan: designed the study, obtained funding, reviewed the results, and helped to write the manuscript. All authors saw and approved the final version of the paper.

Funding

This work was supported by grants from the National Natural Science Foundation of China (81500665), Scientific Research Foundation of Wenzhou (Y20160223), High Level Creative Talents from Department of Public Health in Zhejiang Province, and Project of New Century 551 Talent Nurturing in Wenzhou.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

- [1] Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Arterioscler Thromb Vasc Biol* 2004; 24: e13–e18
- [2] Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; 287: 356–359
- [3] Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. *Diabetes Care* 2004; 27: 2444–2449
- [4] Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol* 2007; 49: 403–414
- [5] Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. *Diabetes Care* 2005; 28: 1769–1778
- [6] Sung KC, Rhee EJ, Ryu S, Kim BJ, Kim BS, Lee WY, Oh KW, Kim YB, Chung PW, Kim H, Byrne CD, Lee KB, Park SW. Increased cardiovascular mortality in subjects with metabolic syndrome is largely attributable to diabetes and hypertension in 159,971 Korean adults. *J Clin Endocrinol Metab* 2015; 100: 2606–2612
- [7] Ryu S, Song J, Choi BY, Lee SJ, Kim WS, Chang Y, Kim DI, Suh BS, Sung KC. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. *Ann Epidemiol* 2007; 17: 245–252
- [8] Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. *Metabolism* 2008; 57: 845–852
- [9] Zhong P, Sun DM, Wu DH, Li TM, Liu XY, Liu HY. Serum total bilirubin levels are negatively correlated with metabolic syndrome in aged Chinese women: A community-based study. *Braz J Med Biol Res* 2017; 50: e5252
- [10] Obokata M, Negishi K, Ohya Y, Okada H, Imai K, Kurabayashi M. A risk score with additional four independent factors to predict the incidence and recovery from metabolic syndrome: Development and Validation in Large Japanese cohorts. *PLoS One* 2015; 10: e0133884
- [11] Lu YH, Lu JM, Wang SY, Li CL, Liu LS, Zheng RP, Tian H, Wang XL, Yang LJ, Zhang YQ, Pan CY. Comparison of the diagnostic criteria of metabolic syndrome by International Diabetes Federation and that by Chinese Medical Association Diabetes Branch. *Zhonghua Yi Xue Za Zhi* 2006; 86: 386–389
- [12] Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr., Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005; 112: 2735–2752
- [13] Doi Y, Ninomiya T, Hata J, Yonemoto K, Arima H, Kubo M, Tanizaki Y, Iwase M, Iida M, Kiyohara Y. Proposed criteria for metabolic syndrome in Japanese based on prospective evidence: The Hisayama study. *Stroke* 2009; 40: 1187–1194
- [14] Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. *Diabetes* 2004; 53: 2087–2094
- [15] Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: A systematic review and dose-response meta-analysis. *Int J Clin Pract* 2015; 69: 136–144
- [16] Lee JH, Um MH, Park YK. The association of metabolic syndrome and Serum gamma-glutamyl transpeptidase: A 4-year cohort study of 3,698 Korean male workers. *Clin Nutr Res* 2013; 2: 67–75
- [17] Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, Levy Y, Brook GJ, Aronson D. Association between elevated liver enzymes and C-reactive protein: Possible hepatic contribution to systemic inflammation in the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2005; 25: 193–197
- [18] Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. *Diabetes Care* 2011; 34: 216–219
- [19] Targher G, Byrne CD. A perspective on metabolic syndrome and nonalcoholic fatty liver disease. *Metab Syndr Relat Disord* 2015; 13: 235–238
- [20] Zhang T, Zhang C, Zhang Y, Tang F, Li H, Zhang Q, Lin H, Wu S, Liu Y, Xue F. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: A prospective cohort study. *Atherosclerosis* 2015; 240: 144–148
- [21] Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I, Yazici M, Keles I. Serum uric acid is a determinant of metabolic syndrome in a population-based study. *Am J Hypertens* 2006; 19: 1055–1062
- [22] Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med* 2007; 120: 442–447
- [23] Tran BT, Jeong BY, Oh JK. The prevalence trend of metabolic syndrome and its components and risk factors in Korean adults: Results from the Korean National Health and Nutrition Examination Survey 2008-2013. *BMC Public Health* 2017; 17: 71